Fishawack Health, a leading commercialization partner for the life science industry, welcomes FIDE to its group—an independent expert-led consultancy specializing in chronic inflammatory skin conditions and offering independent expert insight from leading dermatologists.
Syneos Health announced an agreement to acquire Synteract, a full-service contract research organization (CRO) focused on the biopharmaceutical industry.
Generic drugmaker Aurobindo Pharma called off the company’s $1 billion acquisition plans for multiple assets owned by Sandoz after failing to secure approval from the Federal Trade Commission.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
Spending time in the sun without protection increases the risk of melanoma, but the potentially deadly skin cancer can occur even on sites with minimal sun exposure, doctors warn.
Vical Incorporated and Brickell Biotech Inc. announced a definitive merger agreement under which Brickell would merge with a wholly owned subsidiary of Vical in an all-stock transaction.
The U.S. FDA accepted for review Foamix Pharmaceuticals Ltd.’s New Drug Application (NDA) for FMX101 for treating inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
